Mecobalamin
CAS 13422-55-4
Mecobalamin (CAS 13422-55-4) is a pharmaceutical compound with 0 bioactivity targets and 2,508 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Platelet count decreased | 205 | 199.087 | 10035528 |
| Hepatic function abnormal | 131 | 196.773 | 10019670 |
| Interstitial lung disease | 150 | 181.435 | 10022611 |
| Neutrophil count decreased | 119 | 139.892 | 10029366 |
| Cerebral infarction | 70 | 94.226 | 10008118 |
| White blood cell count decreased | 136 | 90.122 | 10047942 |
| Renal impairment | 119 | 84.96 | 10062237 |
| Drug ineffective | 66 | 79.133 | 10013709 |
| Fatigue | 45 | 77.421 | 10016256 |
| Upper respiratory tract inflammation | 26 | 70.348 | 10049590 |
| Altered state of consciousness | 59 | 69.792 | 10001854 |
| Drug eruption | 57 | 68.984 | 10013687 |
| Decreased appetite | 172 | 67.952 | 10061428 |
| Pneumonia | 254 | 58.804 | 10035664 |
| Lymphocyte count decreased | 54 | 58.786 | 10025256 |
| Anaemia | 189 | 58.02 | 10002034 |
| Liver disorder | 66 | 55.126 | 10024670 |
| Malignant neoplasm progression | 92 | 54.288 | 10051398 |
| Disseminated intravascular coagulation | 45 | 52.476 | 10013442 |
| Spinal compression fracture | 34 | 50.752 | 10041541 |
| Osteonecrosis of jaw | 49 | 50.498 | 10064658 |
| Pneumonia bacterial | 34 | 48.811 | 10060946 |
| Pyrexia | 238 | 48.623 | 10037660 |
| Drug-induced liver injury | 56 | 47.358 | 10072268 |
| Pain | 43 | 46.247 | 10033371 |
| Enterocolitis | 29 | 46.073 | 10014893 |
| Toxicity to various agents | 7 | 44.49 | 10070863 |
| Erythema multiforme | 28 | 39.601 | 10015218 |
| Cardiac failure | 83 | 39.114 | 10007554 |
| Febrile neutropenia | 105 | 38.848 | 10016288 |
| Pneumonia aspiration | 50 | 36.269 | 10035669 |
| Hypopituitarism | 15 | 36.069 | 10021067 |
| Femoral neck fracture | 22 | 35.87 | 10016450 |
| Diabetes mellitus | 58 | 35.578 | 10012601 |
| Toxic encephalopathy | 22 | 35.158 | 10044221 |
| Male sexual dysfunction | 8 | 34.13 | 10057672 |
| Hypoalbuminaemia | 28 | 33.098 | 10020942 |
| Plasma cell myeloma | 47 | 32.532 | 10035226 |
| Hyperuricaemia | 22 | 32.503 | 10020903 |
| Joint swelling | 10 | 31.105 | 10023232 |
| Inappropriate antidiuretic hormone secretion | 28 | 29.843 | 10053198 |
| Blood pressure decreased | 57 | 29.627 | 10005734 |
| Herpes zoster | 58 | 28.944 | 10019974 |
| Treatment failure | 3 | 28.31 | 10066901 |
| Confusional state | 10 | 28.113 | 10010305 |
| Swelling | 7 | 27.793 | 10042674 |
| Peripheral swelling | 8 | 27.61 | 10048959 |
| Aspartate aminotransferase increased | 66 | 27.029 | 10003481 |
| Alopecia | 11 | 26.899 | 10001760 |
| Concomitant disease aggravated | 20 | 26.767 | 10010253 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| METHYLCOBALAMIN | 29421 | SU | MTHSPL |
| mecobalamin | 29421 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Mecobalamin used for in pharmaceutical contexts?
Mecobalamin (CAS 13422-55-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Mecobalamin?
Mecobalamin has 2,508 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Platelet count decreased, Hepatic function abnormal, Interstitial lung disease, Neutrophil count decreased, Cerebral infarction. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Mecobalamin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Methylcobalamin with EU status "permitted".
What clinical phase is Mecobalamin in?
No phase 1-4 clinical development badge is rendered for Mecobalamin because the matched compound identifier rows do not contain a max-phase value.